Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY H SCHNEIDER

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1821074618
CMS profile
263849
Location
CORAL SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$37,586.58

142 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY H SCHNEIDER

NPI 1821074618 · CMS profile ID 263849

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CORAL SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821074618?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY H SCHNEIDER, NPI 1821074618, CMS profile ID 263849. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821074618?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JEFFREY H SCHNEIDER, NPI 1821074618, CMS profile ID 263849. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821074618?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JEFFREY H SCHNEIDER, NPI 1821074618, CMS profile ID 263849, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1821074618?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

142 matching records · $37,586.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 142 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–142 of 142.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $18.4404/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542237 CMS
Gilead Sciences, Inc. $20.5204/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929490175 CMS
ABBVIE INC. $17.0303/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542235 CMS
Ardelyx, Inc. $21.7603/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925731601 CMS
ABBVIE INC. $13.7503/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542233 CMS
ABBVIE INC. $18.7103/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542231 CMS
Janssen Biotech, Inc. $16.1703/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885654479 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.4403/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959701245 CMS
Celgene Corporation $0.6803/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932891357 CMS
Celgene Corporation $19.3403/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932891359 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.0703/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959458509 CMS
RedHill Biopharma Inc. $189.4203/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902936733 CMS
Gilead Sciences, Inc. $2,830.0003/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929435625 CMS
ABBVIE INC. $2.8103/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542229 CMS
Gilead Sciences, Inc. $572.8403/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929460323 CMS
Gilead Sciences, Inc. $96.4403/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929490193 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.6303/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955814164 CMS
Gilead Sciences, Inc. $19.5203/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929490171 CMS
Gilead Sciences, Inc. $1,800.0002/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929435621 CMS
ABBVIE INC. $14.0702/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542227 CMS
Ironwood Pharmaceuticals, Inc $24.9902/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957912499 CMS
ABBVIE INC. $11.7002/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542225 CMS
RedHill Biopharma Inc. $1,320.0002/18/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902936731 CMS
RedHill Biopharma Inc. $113.4202/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902936729 CMS
Ferring Pharmaceuticals Inc. $14.9802/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 875361269 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.3702/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959753039 CMS
Janssen Biotech, Inc. $16.1702/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885654473 CMS
Evoke Pharma, Inc. $11.7702/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913793057 CMS
RedHill Biopharma Inc. $1,320.0002/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902936725 CMS
RedHill Biopharma Inc. $173.8502/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902936727 CMS
ABBVIE INC. $11.8002/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542223 CMS
Nestle HealthCare Nutrition Inc. $18.2102/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902796329 CMS
RedHill Biopharma Inc. $120.7402/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902936723 CMS
Cumberland Pharmaceuticals, Inc. $15.4401/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951787003 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.1901/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955814161 CMS
ABBVIE INC. $15.8201/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542221 CMS
Janssen Biotech, Inc. $16.7301/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885654467 CMS
ABBVIE INC. $18.8001/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542219 CMS
Celgene Corporation $21.2901/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932891349 CMS
ABBVIE INC. $17.3401/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542217 CMS
ABBVIE INC. $15.6301/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891542215 CMS
Gilead Sciences, Inc. $21.7401/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929490179 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $37,398.58 154
PY2020 $23,504.21 98
PY2021 $38,230.03 140
PY2022 $37,586.58 142
PY2023 $33,658.97 103
PY2024 $90,637.30 172
PY2025 $82,792.65 152

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,007,451.28 88
PY2024 Principal investigator $879,487.25 27
PY2023 Principal investigator $31,593.37 4
PY2022 Principal investigator $94,645.00 5
PY2021 Recipient $80.86 1
PY2021 Principal investigator $145,893.73 21
PY2020 Principal investigator $626,445.67 26
PY2019 Recipient $4,300.00 1
PY2019 Principal investigator $917,285.20 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51,384.47 12/11/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,386.36 11/25/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184264351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,599.60 11/20/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,974.00 11/20/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,780.00 11/20/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,527.37 11/14/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184260971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,571.52 11/14/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184260973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27,531.00 11/14/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184260975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,084.16 11/07/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,746.71 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,205.10 10/23/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $69,987.89 10/16/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,673.00 10/16/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,985.00 10/16/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,880.00 10/09/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,612.30 10/03/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36,498.24 10/03/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,229.67 09/23/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,251.64 09/18/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396,831.19 09/10/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235889
Principal investigator 1 Eli Lilly and Company $42,418.00 09/08/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187887546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,827.67 09/03/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235029
Principal investigator 1 Eli Lilly and Company $86,368.70 08/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187887274
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,973.17 08/26/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,387.00 08/26/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,628.00 08/26/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,058.00 08/26/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,513.25 08/21/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,154.79 08/14/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,195.40 08/07/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,468.56 08/07/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,900.37 07/31/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222988
Principal investigator 1 Eli Lilly and Company $206.00 07/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187888688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,114.18 07/22/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,934.38 07/22/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,356.96 07/22/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28,237.56 07/22/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,982.50 07/22/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51,093.00 07/22/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,671.90 07/22/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,264.18 07/22/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,447.90 07/17/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217262
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,375.19 07/10/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,510.38 07/04/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184213035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,866.35 06/24/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,455.00 06/24/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39,825.30 06/24/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,115.00 06/24/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,994.76 06/19/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209300
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,917.37 06/12/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125,918.10 06/12/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.96 06/12/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68,827.50 06/12/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33,430.50 06/12/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,780.00 06/12/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,900.24 06/12/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,150.00 06/12/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,538.38 06/05/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,303.93 05/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184199013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,026.30 05/22/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,392.77 05/15/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,834.32 05/08/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,482.00 04/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,671.24 04/23/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36,219.20 04/15/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183326
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,099.26 04/08/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181976
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,983.77 04/01/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,557.01 03/25/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,100.88 03/19/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174404
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,937.12 03/19/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37,363.50 03/14/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,010.88 03/14/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184173926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,036.70 03/11/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29,926.01 03/04/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,163.56 02/25/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,290.00 02/25/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,979.40 02/25/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70,992.66 02/18/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35,003.24 02/11/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,767.93 02/05/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,621.66 01/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149980
Principal investigator 1 Eli Lilly and Company $12,926.00 01/21/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187888810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $34,378.51 01/21/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28,554.78 01/17/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148237
Principal investigator 1 Eli Lilly and Company $9,710.85 01/15/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187887940
Principal investigator 1 Eli Lilly and Company $739,164.00 01/07/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187889884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60,156.20 01/07/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184146046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,873.88 01/07/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184146048